colistimethate sodium
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
pharma · AML/MDS · Hepatocellular Carcinoma (HCC) · SNTI
Essential Pharma
Essential Pharma Limited
Essential Pharma drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Egham, GB HQ
2000 Founded
111 Employees
Public company Type
SNTI · NYSE Ticker
Company details
- Status
- Public
- HQ
- Egham, GB
- Founded
- 2000
- Employees
- 111
- Programs
- 2
- Drugs
- 3
- Patents
- 95
Essential Pharma pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Essential Pharma drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor positive modulator